LivaNova posts impressive 10.8% revenue increase

• LivaNova’s second-quarter revenue increased 10.8% to $390.6 million, led by growth across its two main business segments.
• GAAP diluted EPS reached $1.93, while adjusted diluted EPS increased to $1.26.
• LivaNova raised its 2026 revenue and adjusted EPS forecasts but lowered its adjusted free cash flow outlook.

LivaNova (NASDAQ:LIVN) reported second-quarter revenue of $390.6 million, up 10.8%, as Cardiopulmonary and Neuromodulation sales increased.

Revenue rose from $352.5 million and exceeded the $380.5 million analyst estimate, while adjusted EPS of $1.26 topped the $1.09 estimate.

Net income reached $108.6 million, aided by a $95.4 million tax benefit, while operating cash flow was $66.6 million and adjusted free cash flow was $45.5 million.

LivaNova raised its 2026 revenue growth forecast to 8%–9% and adjusted EPS guidance to $4.30–$4.40; following the announcement the LivaNova share price was up 3.6% at $85.33.

Cardiopulmonary revenue increased 11.2% to $221.6 million, while Neuromodulation revenue rose 10.1% to $166.9 million.

The company signed a long-term Thermo Fisher supply agreement and reported an 84.5% cumulative response rate using its PolySync sleep-apnea programming algorithm.